Results vary considerably across individuals, and some men report no benefit at all
Key safety findings include: No established LD50: Researchers haven't been able to determine a lethal dose in animal models, even at doses many times higher than therapeutic ranges No observed organ toxicity: Studies examining the effects of BPC-157 on liver, kidney, heart, and other organs haven't shown toxic effects No hormonal disruption: Unlike many compounds used for recovery and healing (such as growth hormone secretagogues or anabolic agents), BPC-157 doesn't appear to alter endocrine function No tumor promotion: Studies conducted to date haven't shown that BPC-157 promotes tumor growth or increases cancer risk, though this is an area that warrants continued monitoring Stable across administration routes: Both oral and injectable BPC-157 have shown comparable safety profiles Reported Side Effects Based on clinical observations and user reports, the side effects of BPC-157 are generally mild and self-limiting: Common Side Effects (Mild, Transient) Injection site reactions: Mild redness, minor swelling, or slight discomfort at the injection site
Effective April 23, 2026, BPC-157 was removed from Category 2, meaning the significant safety concern designation no longer applies
Mortal hyperkalemia disturbance in rats is NO-system related
NADPH is mainly derived from the pentose phosphate pathway, which uses glucose-6-phosphate dehydrogenase (G6PD) as the key enzyme [36]
